Literature DB >> 15059162

The validity of self-reported use of hormone replacement therapy among Danish nurses.

Ellen Leth Løkkegaard1, Søren Påske Johnsen, Berit Lillienthal Heitmann, Claudia Stahlberg, Anette Tønnes Pedersen, Erik Bernhard Obel, Yrsa Andersen Hundrup, Jesper Hallas, Henrik Toft Sørensen.   

Abstract

BACKGROUND: Recent findings from randomized clinical trials on the effects of hormone replacement therapy (HRT) among postmenopausal women contradict findings from observational studies indicating a protective effect on the development of cardiovascular disease. Most observational studies on HRT are based on self-reported data, although data on the validity of HRT in postmenopausal women are sparse.
METHODS: We examined self-reported HRT use from questionnaires administered in 1993 (n = 2694) and again in 1999 (n = 2666) to a cohort of Danish nurses living in two Danish counties compared with prescription-reimbursement data from two administrative databases through the Danish National Health Service.
RESULTS: The sensitivity and specificity of the self-reported, current HRT use in 1993 were 78.4%[95% confidence interval (95% CI) 75.4-81.4] and 98.4% (95% CI 97.8-98.9), respectively. In 1999, the estimates were 74.8% (95% CI 72.0-77.7) and 98.0% (95% CI 97.3-98.8), respectively. None of the factors examined--including age, alcohol intake, physical activity, smoking, presence of hypertension, and body mass index--was strongly associated with validity. We found a relatively high validity of self-reported data on HRT use. Furthermore, agreement between self-reported and registry-based data was not strongly associated with a range of demographic and lifestyle factors.
CONCLUSION: These findings suggest that use of self-reported data is not an important contributor to the apparent discrepancy between observational studies and randomized trials on the cardiovascular effects of HRT use.

Entities:  

Mesh:

Year:  2004        PMID: 15059162     DOI: 10.1111/j.0001-6349.2004.00376.x

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  21 in total

1.  Use of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study.

Authors:  Gitte Vrelits Sørensen; Patricia A Ganz; Steven W Cole; Lars A Pedersen; Henrik Toft Sørensen; Deirdre P Cronin-Fenton; Jens Peter Garne; Peer M Christiansen; Timothy L Lash; Thomas P Ahern
Journal:  J Clin Oncol       Date:  2013-05-06       Impact factor: 44.544

2.  Postmenopausal estrogen therapy and risk of gallstone disease: a population-based case-control study.

Authors:  Maja Hellfritzsch Simonsen; Rune Erichsen; Trine Frøslev; Jørgen Rungby; Henrik Toft Sørensen
Journal:  Drug Saf       Date:  2013-12       Impact factor: 5.606

3.  Hormone replacement therapy, oral contraceptive use, and distal large bowel cancer: a population-based case-control study.

Authors:  Millie D Long; Christopher F Martin; Joseph A Galanko; Robert S Sandler
Journal:  Am J Gastroenterol       Date:  2010-03-30       Impact factor: 10.864

4.  Risk of low-energy hip, wrist, and upper arm fractures among current and previous users of hormone replacement therapy: The Danish Nurse Cohort Study.

Authors:  Yrsa Andersen Hundrup; Susanne Høidrup; Ola Ekholm; Michael Davidsen; Erik Bernhard Obel
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

5.  High concordance between self-reported medication and official prescription database information.

Authors:  Jari Haukka; Jaana Suvisaari; Annamari Tuulio-Henriksson; Jouko Lönnqvist
Journal:  Eur J Clin Pharmacol       Date:  2007-08-22       Impact factor: 2.953

6.  Prescriptions for selective cyclooxygenase-2 inhibitors, non-selective non-steroidal anti-inflammatory drugs, and risk of breast cancer in a population-based case-control study.

Authors:  Deirdre P Cronin-Fenton; Lars Pedersen; Timothy L Lash; Søren Friis; John A Baron; Henrik T Sørensen
Journal:  Breast Cancer Res       Date:  2010-03-01       Impact factor: 6.466

7.  No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications.

Authors:  Thomas P Ahern; Lars Pedersen; Deirdre P Cronin-Fenton; Henrik Toft Sørensen; Timothy L Lash
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-08-18       Impact factor: 4.254

8.  Postmenopausal hormone therapy and non-Hodgkin lymphoma: a pooled analysis of InterLymph case-control studies.

Authors:  E V Kane; L Bernstein; P M Bracci; J R Cerhan; L Costas; L Dal Maso; E A Holly; C La Vecchia; K Matsuo; S Sanjose; J J Spinelli; S S Wang; Y Zhang; T Zheng; E Roman; A Kricker
Journal:  Ann Oncol       Date:  2012-09-11       Impact factor: 32.976

9.  Glucocorticoid prescriptions and breast cancer recurrence: a Danish nationwide prospective cohort study.

Authors:  L W Lietzen; T Ahern; P Christiansen; A B Jensen; H T Sørensen; T L Lash; D P Cronin-Fenton
Journal:  Ann Oncol       Date:  2014-09-15       Impact factor: 32.976

10.  Cessation of hormone replacement therapy after reports of adverse findings from randomized controlled trials: evidence from a British Birth Cohort.

Authors:  Gita Mishra; Helen Kok; Russell Ecob; Rachel Cooper; Rebecca Hardy; Diana Kuh
Journal:  Am J Public Health       Date:  2006-05-30       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.